Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study will recruit 159 HIV-infected men with alcohol use disorders (AUDs). Men will be
randomized to receive either oral naltrexone for the treatment of alcohol use disorder or
placebo. Men with acute, recent or established HIV infection will receive antiretroviral
treatment (ART) and be randomized to oral naltrexone or placebo. The purpose of this study is
to see whether use of oral naltrexone improves medication compliance, and therefore HIV viral
load suppression, among men with alcohol use disorder. The study will also assess the impact
of oral naltrexone on alcohol use behaviors in this population.
Phase:
Phase 4
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Asociación Civil Impacta Salud y Educación, Peru Yale University